| Literature DB >> 21083886 |
Cees van Nieuwkoop1, Tobias N Bonten, Jan W van't Wout, Ed J Kuijper, Geert H Groeneveld, Martin J Becker, Ted Koster, G Hanke Wattel-Louis, Nathalie M Delfos, Hans C Ablij, Eliane M S Leyten, Jaap T van Dissel.
Abstract
INTRODUCTION: Guidelines recommend that two blood cultures be performed in patients with febrile urinary tract infection (UTI), to detect bacteremia and help diagnose urosepsis. The usefulness and cost-effectiveness of this practice have been criticized. This study aimed to evaluate clinical characteristics and the biomarker procalcitonin (PCT) as an aid in predicting bacteremia.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21083886 PMCID: PMC3220019 DOI: 10.1186/cc9328
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Baseline characteristics of 581 patients presenting with febrile UTI.
| Characteristic at presentation | All patients | Non-bacteremic | Bacteremic |
|
|---|---|---|---|---|
| Demographics | ||||
| Age, years, median (IQR) | 66 (46 to 78) | 63 (42 to 77) | 74 (60 to 84) | <0.001 |
| Male sex | 219 (38) | 163 (36) | 56 (43) | 0.175 |
| Nursing home residency | 29 (5) | 20 (4) | 9 (7) | 0.262 |
| Co-morbidity | ||||
| Any | 301 (52) | 226 (50) | 75 (57) | 0.156 |
| Diabetes mellitus | 96 (17) | 65 (14) | 31 (24) | 0.012 |
| Malignancya | 63 (11) | 44 (10) | 19 (15) | 0.126 |
| Urinary catheterb | 45 (8) | 30 (7) | 15 (12) | 0.093 |
| Urinary tract disorderc | 144 (25) | 110 (24) | 34 (26) | 0.725 |
| Immunocompromised | 87 (15) | 68 (15) | 19 (15) | 0.864 |
| History, Signs and Symptoms | ||||
| Antibiotic UTI treatmentd | 167 (29) | 119 (26) | 48 (37) | 0.023 |
| Fever duration, hours, median (IQR)e | 24 (12 to 53) | 24 (12 to 48) | 24 (12 to 72) | 0.791 |
| Altered mental status | 46 (8) | 27 (6) | 19 (15) | 0.002 |
| Shaking chills | 320 (55) | 236 (52) | 84 (64) | 0.018 |
| Costovertebral tenderness | 352 (61) | 283 (63) | 69 (53) | 0.035 |
| Temperature, °C, mean ± SD | 38.6 ± 1.05 | 38.5 ± 1.06 | 38.8 ± 0.99 | 0.001 |
| MAP, mmHg, mean ± SD, | 101 ± 17 | 102 ± 17 | 100 ± 19 | 0.479 |
| HR, beats/minute, mean ± SD | 93 ± 18 | 91 ± 17 | 98 ± 20 | <0.001 |
| PCT, μg/L, median (IQR) | 0.41 (0.13 to 1.68) | 0.25 (0.10 to 0.90) | 2.29 (0.72 to 9.07) | <0.001 |
Data are presented as n (%) unless otherwise stated. IQR, interquartile range; SD, standard deviation; MAP, mean arterial pressure; HR, heart rate; PCT, procalcitonin. a Defined as any cancer except basal- or squamous-cell cancer of the skin that was active within the previous year. b Indwelling urethral catheter (n = 36), supra-pubic catheter (n = 7), intermittent urethral self-catherization (n = 2). c Defined as the presence of any functional or anatomical abnormality of the urinary tract. d Present oral antibiotic treatment for non-febrile UTI (that is, fever developed during UTI treatment). e Missing value in 81 patients.
Figure 1Predictive value of procalcitonin (PCT) level for the diagnosis of bacteremia in 581 adults presenting with febrile urinary tract. AUC, area under curve; ROC, receiver operating characteristic; NPV, negative predictive value; PPV, positive predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio.
Multivariate logistic regression models predicting bacteremia in 581 patients with febrile UTI.
| Multivariate OR | |||
|---|---|---|---|
| 0.145 | |||
| Age >65 years | 2.4 (1.5 to 3.8) | <0.001 | |
| Temperature >38.6°C | 2.1 (1.3 to 3.3) | 0.001 | |
| Altered mental status | 1.8 (0.9 to 3.5) | 0.093 | |
| Heart rate >100/minute | 1.7 (1.1 to 2.7) | 0.015 | |
| Diabetes mellitus | 1.6 (1.0 to 2.7) | 0.063 | |
| Shaking chills | 1.5 (1.0 to 2.3) | 0.052 | |
| Antibiotic UTI treatment | 1.5 (0.9 to 2.3) | 0.085 | |
| 0.293 | |||
| Age >65 years | 1.6 (1.0 to 2.5) | 0.059 | |
| Temperature >38.6°C | 1.7 (1.1 to 2.7) | 0.019 | |
| Altered mental status | 2.0 (1.0 to 4.2) | 0.054 | |
| Diabetes mellitus | 1.8 (1.0 to 3.1) | 0.035 | |
| PCT > 0.25 μg/l | 14.7 (6.6 to 32.6) | <0.001 | |
| 0.252 | |||
| PCT > 0.25 μg/l | 18.0 (8.2 to 39.5) | <0.001 |
UTI: urinary tract infection; OR: Odds Ratio; CI: confidence interval; PCT: procalcitonin; R2: Nagelkerke's R2.
Model 1 = Clinical model including all clinical variables of Table 1 with P-value < 0.2 in univariate analysis.
Model 2 = Model 1 + PCT > 0.25 μg/l. Model 3 = PCT > 0.25 μg/l only.
Predictive value of different models predicting bacteremia in 581 adults with febrile UTI.
| No. patients without risk factor (%) | Sensitivity, % | Specificity, % | NPV, % | PPV, % | LR + | LR - | ||
|---|---|---|---|---|---|---|---|---|
| Risk factor | A | 271 (47) | 70 (62 to 78) | 52 (46 to 56) | 86 (81 to 89) | 30 (25 to 35) | 1.45 (1.25 to 1.68) | 0.58 (0.44 to 0.75) |
| Risk factors | A, B | 127 (22) | 90 (83 to 94) | 25 (21 to 30) | 90 (83 to 94) | 26 (22 to 30) | 1.21 (1.12 to 1.30) | 0.39 (0.23 to 0.66) |
| Risk factors | A, B, C | 112 (19) | 93 (87 to 97) | 23 (19 to 27) | 92 (85 to 96) | 26 (22 to 30) | 1.21 (1.13 to 1.29) | 0.30 (0.16 to 0.57) |
| Risk factor | B | 270 (46) | 68 (60 to 76) | 51 (46 to 56) | 85 (80 to 89) | 29 (24 to 34) | 1.39 (1.21 to 1.62) | 0.61 (0.48 to 0.80) |
| Risk factors | B, D | 229 (39) | 78 (70 to 85) | 45 (40 to 49) | 88 (83 to 92) | 29 (25 to 34) | 1.42 (1.26 to 1.61) | 0.48 (0.34 to 0.67) |
| Risk factors | P, B | 140 (24) | 97 (92 to 99) | 30 (26 to 34) | 97 (92 to 99) | 29 (25 to 33) | 1.39 (1.30 to 1.49) | 0.10 (0.04 to 0.27) |
| Risk factors | P, B, D | 116 (20) | 97 (92 to 99) | 25 (21 to 29) | 97 (91 to 99) | 27 (23 to 32) | 1.29 (1.21 to 1.37) | 0.12 (0.05 to 0.33) |
| PCT > 0.25 µg/l | 234 (40) | 95 (89 to 98) | 50 (46 to 55) | 97 (94 to 99) | 36 (31 to 41) | 1.91 (1.73 to 2.11) | 0.11 (0.05 to 0.22) |
NPV, negative predictive value; PPV, positive predictive value; LR+, positive likelihood ration; LR-, negative likelihood ratio; A, Age >65 years; B, Temperature >38.6°C; C, heart rate >100/minute; D, diabetes mellitus; P, PCT > 0.25 μg/l. For Model 1 and Model 2 the corresponding sensitivity, specificity, NPV, PPV, LR+ and LR- are calculated using a cutoff value of ≥1 risk factor.
Figure 2Relation between procalcitonin level at presentation with .